CAPTEM Regimen (Capecitabine + Temozolomide) (Xeloda + Temodar) — Clinical FAQs

Question 1

What is CAPTEM Regimen (Capecitabine + Temozolomide) FDA-approved to treat?

Accepted Answer

CAPTEM Regimen (Capecitabine + Temozolomide) is FDA-approved for the following oncology indications: 1. No FDA approval for the CAPTEM combination as a regimen; component agents have individual approvals (temozolomide: glioblastoma and anaplastic astrocytoma; capecitabine: colorectal cancer, breast cancer, gastric cancer). CAPTEM is used off-label for pancreatic NETs..

Question 2

How does CAPTEM Regimen (Capecitabine + Temozolomide) work (mechanism of action)?

Accepted Answer

CAPTEM is a synergistic combination regimen exploiting a mechanistically distinct two-drug interaction. Temozolomide is an oral imidazotetrazine prodrug that spontaneously converts to MTIC, which methylates the O6-position of guanine, inducing DNA strand breaks and apoptosis. Capecitabine is an oral fluoropyrimidine prodrug converted to 5-fluorouracil (5-FU) preferentially in tumor tissue via the enzyme thymidine phosphorylase (TP). Critically, 5-FU — generated from capecitabine — is a potent inhibitor of thymidylate synthase (TS), depleting dTTP pools and impairing DNA repair of temozolomide-induced lesions. Additionally, capecitabine upregulates TP expression in tumor cells, increasing local 5-FU concentrations. This biochemical modulation provides the mechanistic rationale for combining the two agents: capecitabine-derived 5-FU impairs the base excision repair pathway that corrects O6-methylguanine adducts, thereby enhancing temozolomide cytotoxicity. The combination also depletes MGMT (O6-methylguanine-DNA methyltransferase), the primary resistance enzyme for temozolomide, by providing sustained S-phase cytotoxicity. Together, these mechanisms yield synergistic cytotoxicity in neuroendocrine tumor cells that exceeds either agent alone.

Question 3

How is CAPTEM Regimen (Capecitabine + Temozolomide) administered?

Accepted Answer

CAPTEM Regimen (Capecitabine + Temozolomide) is administered Oral (PO). Standard CAPTEM dosing: Capecitabine 750 mg/m² orally TWICE DAILY on days 1–14 of a 28-day cycle, plus Temozolomide 200 mg/m² orally ONCE DAILY on days 10–14 of the same 28-day cycle (the 5-day overlap is intentional — capecitabine pre-treatment modulates TS and upregulates TP before the temozolomide dosing window begins).

Question 4

What are the most common side effects of CAPTEM Regimen (Capecitabine + Temozolomide)?

Accepted Answer

The most commonly reported side effects of CAPTEM Regimen (Capecitabine + Temozolomide) (≥10% incidence) include: Fatigue (≥50%), Myelosuppression: lymphopenia (universal with temozolomide), thrombocytopenia, neutropenia, Nausea and vomiting (moderate; both agents), Palmar-plantar erythrodysesthesia / hand-foot syndrome (capecitabine; ~30–40%; dose-dependent), Diarrhea (capecitabine) and others (10 total). Consult your oncologist for complete prescribing information.

Question 5

Does CAPTEM Regimen (Capecitabine + Temozolomide) have a black box warning?

Accepted Answer

Yes. CAPTEM Regimen (Capecitabine + Temozolomide) carries FDA black box warning(s) regarding: 1. Myelosuppression (temozolomide): severe thrombocytopenia and neutropenia; monitor CBC on day 22 and day 28 of each cycle. 2. Capecitabine — Coagulopathy and bleeding: capecitabine significantly alters coagulation parameters in patients on warfarin, sometimes causing fatal hemorrhage. Anticoagulation with warfarin should be replaced by LMWH or a DOAC where possible; if warfarin is used, INR must be monitored very frequently. 3. Capecitabine — Severe skin reactions (Hand-Foot Syndrome, SJS, TEN): severe palmar-plantar erythrodysesthesia requiring dose interruption or discontinuation.

Question 6

Is CAPTEM Regimen (Capecitabine + Temozolomide) safe during pregnancy?

Accepted Answer

CAPTEM Regimen (Capecitabine + Temozolomide) pregnancy safety: Category D — Both agents cause fetal harm. Capecitabine is teratogenic and fetotoxic in animals; temozolomide is mutagenic, teratogenic, and carcinogenic. Effective contraception required during treatment and for at least 6 months after the last dose of either agent. Breastfeeding should be discontinued during treatment.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

CAPTEM Regimen (Capecitabine + Temozolomide) — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms